[go: up one dir, main page]

WO2009018088A3 - Imaging of alpha-synuclein - Google Patents

Imaging of alpha-synuclein Download PDF

Info

Publication number
WO2009018088A3
WO2009018088A3 PCT/US2008/071017 US2008071017W WO2009018088A3 WO 2009018088 A3 WO2009018088 A3 WO 2009018088A3 US 2008071017 W US2008071017 W US 2008071017W WO 2009018088 A3 WO2009018088 A3 WO 2009018088A3
Authority
WO
WIPO (PCT)
Prior art keywords
imaging
alpha
synuclein
synucleinopathy
disease
Prior art date
Application number
PCT/US2008/071017
Other languages
French (fr)
Other versions
WO2009018088A2 (en
Inventor
Peter T Lansbury
Craig J Justman
Leslie Shinobu
Original Assignee
Link Medicine Corp
Peter T Lansbury
Craig J Justman
Leslie Shinobu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Link Medicine Corp, Peter T Lansbury, Craig J Justman, Leslie Shinobu filed Critical Link Medicine Corp
Publication of WO2009018088A2 publication Critical patent/WO2009018088A2/en
Publication of WO2009018088A3 publication Critical patent/WO2009018088A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Radiolabeled alpha-synuclein binding agents are provided that are useful in imaging alpha-synucleing deposits in the brain of subjects with a synucleinopathy or susceptible to a synucleinopathy. The agents are particularly useful in imaging via PET and SPECT nuclear medicine imaging. The imaging techniques may be used to diagnose a patient, follow the progression of disease, or follow treatment of the disease.
PCT/US2008/071017 2007-08-01 2008-07-24 Imaging of alpha-synuclein WO2009018088A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95337907P 2007-08-01 2007-08-01
US60/953,379 2007-08-01

Publications (2)

Publication Number Publication Date
WO2009018088A2 WO2009018088A2 (en) 2009-02-05
WO2009018088A3 true WO2009018088A3 (en) 2009-03-19

Family

ID=40305199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/071017 WO2009018088A2 (en) 2007-08-01 2008-07-24 Imaging of alpha-synuclein

Country Status (1)

Country Link
WO (1) WO2009018088A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9207298B2 (en) 2011-03-23 2015-12-08 Millikelvin Technologies Llc Techniques, systems and machine readable programs for magnetic resonance
US8629135B2 (en) 2008-07-14 2014-01-14 Queen's University At Kingston Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer
US8566961B2 (en) * 2008-08-08 2013-10-22 Absolute Software Corporation Approaches for a location aware client
US9714995B2 (en) 2011-03-23 2017-07-25 Millikelvin Technologies Llc Techniques, systems and machine readable programs for magnetic resonance
US20140266197A1 (en) * 2013-03-15 2014-09-18 Millikelvin Technologies Llc Techniques, systems and machine readable programs for magnetic resonance
CN105277632A (en) * 2014-07-24 2016-01-27 江苏维赛科技生物发展有限公司 Method for detecting cyproheptadine residual quantity in swine urine through high performance liquid-tandem mass spectrometry
AU2016222550B2 (en) 2015-02-27 2020-07-16 Dechra Limited Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
WO2017053834A1 (en) * 2015-09-25 2017-03-30 Board Of Regents Of The University Of Nebraska Mibg analogs and uses thereof
CN111803473A (en) * 2019-04-10 2020-10-23 云南帕精生物科技有限公司 Application of nortriptyline in treating Parkinson's disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026020A2 (en) * 2000-09-26 2002-04-04 The Brigham And Women's Hospital, Inc. Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics
WO2004100998A2 (en) * 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20050196818A1 (en) * 2003-11-08 2005-09-08 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
WO2007011907A2 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026020A2 (en) * 2000-09-26 2002-04-04 The Brigham And Women's Hospital, Inc. Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics
WO2004100998A2 (en) * 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20050196818A1 (en) * 2003-11-08 2005-09-08 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
WO2007011907A2 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUNNETT ET AL.: "Prospects for new restorative and neurprotective treatments in parkinson's disease", NATURE, vol. 399, 1999, pages A32 - A39 *
LI ET AL.: "Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation", THE JOURNAL OF NEUROSCIENCE, vol. 24, no. 33, 2004, pages 7400 - 7409 *
SURATT ET AL.: "Recognition of Psychostimulants, Antidepressants, and Other Inhibitors of Synaptic Neurotransmitter Uptake by the Plasma Membrane Monoamine Transporters", AAPS JOURNAL, vol. 7, no. 3, 2005, pages E739 - E751 *

Also Published As

Publication number Publication date
WO2009018088A2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
WO2009018088A3 (en) Imaging of alpha-synuclein
Vlaeyen et al. Pain-related fear: Exposure-based treatment of chronic pain.
WO2015092020A3 (en) Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
HRP20180230T8 (en) ANTIBODIES BINDING TO PROTOFIBRILS AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES IN PARKINSON'S DISEASE, LEWY BODY DEMENTIA AND OTHER ALPHA SYNUCLEINOPATES
WO2008010227A3 (en) Imaging protocols
MX353727B (en) Treatment of synucleinopathies.
IL180565A0 (en) An improved stopcock for administering medicaments into the patient's body
EP1804661A4 (en) Integrated disease diagnosis and treatment system
WO2007010534A3 (en) Imaging protocols
GB0700436D0 (en) Impulse therapy for enhanced blood circulation in the body
BRPI0812384A2 (en) TREATMENT, DIAGNOSTIC AND DISEASE TREATMENT METHODS ASSOCIATED WITH FGF21
EP1937109A4 (en) Radiation therapy patient couch top compatible with diagnostic imaging
PL1824523T3 (en) Method of cardiac imaging with the use of hyperpolarized 13c-pyruvate
IL204584A0 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
WO2008075040A3 (en) Radioactive pet agents for imaging ccr5 in vivo
WO2009009175A3 (en) Spectral imaging device for hirschsprung's disease
IL205561A0 (en) Non-invasive medical data collecting assembly
WO2008147483A3 (en) Neurogenic compounds
EP1885185A4 (en) Cellular cardiomyoplasty as supportive therapy in patients with heart disease
IL191365A0 (en) Agent for use in the case of disorders of blood sugar metabolism, including diabetes
IL218456A (en) Diagnostic composition comprising a derivative of bis(2,4,6-triiodophenyl) and methods for diagnosis and in vivo imaging detection using the same
BRPI1012325A2 (en) use of microrna-199b-5p in the medical and diagnostic field. "
ZA200711163B (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
GB2493313B (en) Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldt-jakob disease or diabetes mellitus
FR2928823B1 (en) DEVICE FOR INVESTIGATING BY VISION AND AUSCULTATION, IN PARTICULAR IN PARTS OF THE HUMAN BODY.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08796540

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08796540

Country of ref document: EP

Kind code of ref document: A2